Navigation Links
Neuralstem President And CEO To Present At The 2013 Rodman & Renshaw Annual Healthcare Conference
Date:9/3/2013

/span> disease, in February 2013, and has received FDA approval to begin Phase II. Neuralstem has been awarded orphan status designation by the FDA for its ALS cell therapy.

In addition to ALS, the company is also targeting major central nervous system conditions with its NSI-566 cell therapy platform, including spinal cord injury, ischemic stroke and glioblastoma (brain cancer). The company received approval to commence a Phase I safety trial in chronic spinal cord injury in January 2013.

Neuralstem also has the ability to generate stable human neural stem cell lines suitable for the systematic screening of large chemical libraries. Through this proprietary screening technology, Neuralstem has discovered and patented compounds that may stimulate the brain's capacity to generate new neurons, possibly reversing the pathologies of some central nervous system conditions.  The company is in the last cohort of a Phase Ib safety trial evaluating NSI-189, its first neurogenic small molecule compound, for the treatment of major depressive disorder (MDD). Additional indications could include traumatic brain injury (TBI), Alzheimer's disease, and post-traumatic stress disorder (PTSD).

For more information, please visit www.neuralstem.com or connect with us on Twitter, Facebook and LinkedIn

Cautionary Statement Regarding Forward Looking Information                                                      

This news release may contain forward-looking
'/>"/>

SOURCE Neuralstem, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Neuralstem ALS Stem Cell Trial Featured on Fox Atlanta
2. Neuralstem President and CEO to Update Ongoing ALS and NSI-189/Major Depressive Disorder Trials at 2012 Biotech Showcase
3. Neuralstem President and CEO to Present at BIO CEO & Investor Conference 2012
4. Neuralstem Announces Closing of $5.2-Million Registered Direct Offering
5. Fourteenth Patient Dosed in Neuralstem ALS Stem Cell Trial
6. Neuralstem CEO to Present at the World Stem Cells and Regenerative Medicine Congress in London
7. Neuralstem Receives Notice Of Issuance For Patent Covering Human Neural Cell Transplantation For Neurodegenerative Conditions
8. Neuralstem President And CEO To Present At The 2012 Rodman & Renshaw Annual Healthcare Conference
9. Neuralstem Cells Induce Significant Functional Improvement In Permanent Rat Spinal Cord Injury, Cell Study Reports
10. Neuralstem Announces 2012 Financial Results, Provides Clinical Trials Update
11. Neuralstem Reports First Quarter Financial Results And Provides Business And Clinical Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... Charm Sciences, Inc. is pleased to ... Grain Inspection, Packers and Stockyards Administration (GIPSA) has ... to monitor aflatoxin in grains utilizing Charm’s ROSA ... Aflatoxin Quantitative Test (solvent-based). , The Charm ... Extraction Technology to extract aflatoxin from the sample ...
(Date:5/21/2015)... TORONTO , May 21, 2015 /PRNewswire/ - SQI ... SQIDF),a life sciences company that develops and commercializes proprietary ... its financial and operational results for the second fiscal ... the quarter the Company continued to advance business with ... Andrew Morris , President and CEO of SQI. ...
(Date:5/21/2015)... , May 21, 2015  Susan Hedstrom, Executive ... a nonprofit organization dedicated to supporting research to ... (PWS), announced today that FPWR has received the ... Irina Shaulov contributed $1 million in support ... "Our gift ...
(Date:5/21/2015)... 2015  The EveryLife Foundation for Rare Diseases ... Amy Klobuchar (D-MN) today for introducing ... Treatments, or OPEN ACT. Supported by ... this bipartisan legislation promises to rapidly bring hundreds ... disease patients by incentivizing drug makers to "repurpose" ...
Breaking Biology Technology:USDA-GIPSA (FGIS) Awards 5 Year Contract for Aflatoxin Tests to Charm Sciences 2SQI Diagnostics Reports Second Quarter Financial Results 2SQI Diagnostics Reports Second Quarter Financial Results 3SQI Diagnostics Reports Second Quarter Financial Results 4SQI Diagnostics Reports Second Quarter Financial Results 5SQI Diagnostics Reports Second Quarter Financial Results 6SQI Diagnostics Reports Second Quarter Financial Results 7SQI Diagnostics Reports Second Quarter Financial Results 8The Foundation for Prader-Willi Research Receives $1M Contribution in Support of Clinical Initiatives 2Advocates Cheer Senate Leaders for Introducing Bipartisan Bill to Increase Number of Rare Disease Treatments 2
... 8 A study in the June issue of ... demonstrates that the Hepascore(TM) liver fibrosis blood-serum test panel ... fibrosis in patients with chronic hepatitis C (HCV), potentially ... care for staging fibrosis, in a particular subset of ...
... Interactive Agency Recognized for Excellence in Healthcare Marketing , ... Group , the premier strategic interactive marketing agency serving ... the 2009 Aster Awards with the ... healthcare marketing campaigns for DePuy Orthopaedics and AstraZeneca. ...
... , Amerinet Offering AccuVein,s AV300 Hand-Held Vein Illumination Device to ... June 8 AccuVein LLC today announced a three year ... world,s first hand-held, non-contact vein illumination device to its members. ... a patient,s skin revealing vein position to help the healthcare ...
Cached Biology Technology:Study Finds Noninvasive Blood Test for Liver Fibrosis May Alleviate Need for Liver Biopsies for Some Patients with Chronic Hepatitis C 2Study Finds Noninvasive Blood Test for Liver Fibrosis May Alleviate Need for Liver Biopsies for Some Patients with Chronic Hepatitis C 3Study Finds Noninvasive Blood Test for Liver Fibrosis May Alleviate Need for Liver Biopsies for Some Patients with Chronic Hepatitis C 4Cadient Group Brings Home the Gold and Two Bronze Aster Awards 2AccuVein Inks National Three-Year Group Purchasing Deal With Amerinet 2
(Date:4/20/2015)... Calif. , April 20, 2015 Huntington ... Gabriel Valley to implant a new miniaturized, wireless monitoring ... System is the first and only FDA-approved heart failure ... hospital admissions when used by physicians to manage heart ... sensor that is implanted in the pulmonary artery (PA) ...
(Date:4/13/2015)... According to a recently ... & Opportunities, 2020", the global biometrics market is ... till 2020. The biometrics market is garnering attention ... review of biometric management systems. The constant development ... greater efficiency, are resulting in increasing installation of ...
(Date:4/6/2015)... , Apr. 6, 2015 NXT-ID, Inc. ... a biometric authentication company focused on the growing ... filed provisional patent 62/143028 for MINIATURE, ... ENERGY TRANSFER  NXT-ID introduces a new ... This patent surrounds the use of miniature antenna ...
Breaking Biology News(10 mins):Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3Global Biometrics Market to Cross US$ 21 Billion by 2020: TechSci Research 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 3NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 4
... demand for cargo transport, has inadvertently opened the flood ... has mapped the most detailed forecast to date for ... of cargo ships. Scientists from the Universities of ... data and biological records to assess the risk of ...
... the quality of life for many cancer patients. Many ... to DNA. The public has an opportunity to learn ... drugs and how laboratory research may lead to novel targets ... , a professor of chemistry at the University ...
... May 3, 2013 In a climate as prone ... heat, light and cool. Fortunately, innovative solutions are being ... Network (SNEBRN), a nationwide university initiative headquartered at Concordia, ... from Natural Resources Canada (NRCan). "Through the ...
Cached Biology News:Researchers calculate the global highways of invasive marine species 2Researchers calculate the global highways of invasive marine species 3How do anticancer drugs work? 2How do anticancer drugs work? 3$1 million for smart energy solutions 2
...
Mouse monoclonal [IFR0104] to Salmonella enteriditis ( Abpromise for all tested applications)....
Marmoset plasma and serum - various quantities available...
Natural Mouse Laminin is purified from the Engelbreth-Holm-Swarm (EHS) sarcoma and is provided in Tris-buffered saline....
Biology Products: